A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface
Public ClinicalTrials.gov record NCT04752215. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A First-in-human Phase I, Non-randomized, Open-label, Multi-center Dose-escalation Trial of BI 765049 and BI 765049 + Ezabenlimab Administered by Parenteral Administration(s) in Patients With Malignant Solid Tumors Expressing B7-H6.
Study identification
- NCT ID
- NCT04752215
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 67 participants
Conditions and interventions
Interventions
- BI 765049 Drug
- ezabenlimab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 17, 2021
- Primary completion
- Nov 18, 2024
- Completion
- Dec 16, 2024
- Last update posted
- Feb 1, 2026
2021 – 2024
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| Valkyrie Clinical Trials | Los Angeles | California | 90067 | — |
| University of California Irvine | Orange | California | 92868 | — |
| HealthONE | Denver | Colorado | 80218 | — |
| MD Anderson Cancer Center Orlando | Orlando | Florida | 32806 | — |
| Florida Cancer Specialists-Sarasota-61670 | Sarasota | Florida | 34232 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Norton Healthcare - Norton Cancer Institute - Louisville | Louisville | Kentucky | 40202 | — |
| New York University Langone Medical Center | New York | New York | 10016 | — |
| Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Tennessee Oncology, PLLC-Nashville-52568 | Nashville | Tennessee | 37203 | — |
| Mary Crowley Cancer Research Center | Dallas | Texas | 75230 | — |
| Baylor University Medical Center | Dallas | Texas | 75246 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04752215, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 1, 2026 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04752215 live on ClinicalTrials.gov.